Global Markets Directs, 'T-Cell
Lymphomas - Pipeline Review, H2 2013', provides an overview of the indications
therapeutic pipeline. This report provides information on the therapeutic
development for T-Cell Lymphomas, complete with latest updates, and special
features on late-stage and discontinued projects. It also reviews key players
involved in the therapeutic development for T-Cell Lymphomas. T-Cell Lymphomas
- Pipeline Review, Half Year is built using data and information sourced from
Global Markets Directs proprietary databases, Company/University websites, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put
together by Global Markets Directs team.Note: Certain sections in the report
may be removed or altered based on the availability and relevance of data for
the indicated disease.
Scope * A snapshot of the global
therapeutic scenario for T-Cell Lymphomas. * A review of the T-Cell Lymphomas
products under development by companies and universities/research institutes
based on information derived from company and industry-specific sources. * Coverage of products based on
various stages of development ranging from discovery till registration stages. * A feature on pipeline projects on
the basis of monotherapy and combined therapeutics. * Coverage of the T-Cell Lymphomas
pipeline on the basis of route of administration and molecule type. * Key discontinued pipeline
projects. * Latest news and deals relating to
the products.
Reasons to buy * Identify and understand important
and diverse types of therapeutics under development for T-Cell Lymphomas. * Identify emerging players with
potentially strong product portfolio and design effective counter-strategies to
gain competitive advantage. * Plan mergers and acquisitions
effectively by identifying players of the most promising pipeline. * Devise corrective measures for
pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of
Indication therapeutics. * Develop and design in-licensing
and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope. * Modify the therapeutic portfolio
by identifying discontinued projects and understanding the factors that drove
them from pipeline.
To order this report: Email: support@researchonglobalmarkets.com US:
+1 866 325 7446 UK: +44 203 514 2363 India: +91 22 4098 7600 SOURCE: Researchonglobalmarkets.com
RELATED LINK: T-Cell Lymphomas - Pipeline Review, H2 2013
RELATED VIDEO:
| 
